Adamas Announces New Employment Inducement Grant
May 09 2018 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the
compensation committee of the company’s board of directors granted
four new employees the option to purchase an aggregate of 19,622
shares of the company’s common stock, at a per share exercise price
of $31.34, the closing trading price on May 7, 2018, and restricted
stock units to acquire 3,268 shares of the company’s common stock.
The stock options and restricted stock units vest over four years
and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016
Inducement Plan, which was approved by the company's board of
directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global
Market for equity grants to induce new employees to enter into
employment with the company.
About Adamas Pharmaceuticals,
Inc.Adamas’ goal is to create and commercialize a new
generation of medicines intended to lessen the burden of chronic
neurologic diseases on patients, caregivers and society using its
deep understanding of time-dependent biology. The company is
focused on the commercial launch of GOCOVRI™ (amantadine) extended
release capsules (previously ADS-5102), the first and only
FDA-approved medicine for the treatment of dyskinesia in patients
with Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications, and delivering on its
pipeline of differentiated investigational programs. Those programs
include: ADS-5102 in development for the treatment of multiple
sclerosis walking impairment; and ADS-4101, a high-dose, modified
release lacosamide in development for the treatment of partial
onset seizures in patients with epilepsy. For more information
about Adamas and its unique approach to developing medicines based
on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024